Subtopic Deep Dive
Mitochondrial Dysfunction Cisplatin Nephrotoxicity
Research Guide
What is Mitochondrial Dysfunction Cisplatin Nephrotoxicity?
Mitochondrial dysfunction in cisplatin nephrotoxicity refers to cisplatin-induced damage to renal cell mitochondria, including mtDNA lesions, electron transport chain inhibition, ROS overproduction, and bioenergetic failure leading to acute kidney injury.
Cisplatin triggers mitochondrial ROS production that depends on redox status and impairs energy functions in kidney cells (Marullo et al., 2013, 756 citations). This dysfunction involves oxidative stress, redox imbalance, and apoptosis in rat kidney mitochondria (dos Santos et al., 2007, 321 citations). Over 10 key papers document these mechanisms, with interventions targeting mitophagy and PGC-1α.
Why It Matters
Preserving mitochondrial integrity prevents progression from cisplatin nephrotoxicity to chronic kidney disease, enabling safer chemotherapy dosing for cancers like ovarian and testicular tumors. Marullo et al. (2013) showed mitochondrial ROS drives cytotoxicity, informing antioxidant therapies. Özkök and Edelstein (2014) detailed AKI pathophysiology, guiding clinical renoprotection strategies. Holditch et al. (2019) reviewed biomarkers and interventions, supporting translation to patient care.
Key Research Challenges
Quantifying Mitochondrial ROS
Measuring cisplatin-induced ROS in renal mitochondria remains inconsistent due to variable redox states. Marullo et al. (2013) linked ROS to bioenergetic functions but noted assay limitations. Standardized in vivo detection methods are needed for preclinical models.
Balancing Renoprotection Tumor Efficacy
Interventions like PGC-1α activation protect kidneys but risk reducing cisplatin's anticancer effects. Volarević et al. (2019) highlighted this knife-edge balance in molecular mechanisms. Selective mitochondrial targeting lacks clinical validation.
Mitophagy Regulation in AKI
Dysregulated mitophagy exacerbates fission-fusion imbalance post-cisplatin exposure. dos Santos et al. (2007) observed energetic metabolism impairment tied to apoptosis. Identifying regulators beyond PGC-1α requires advanced renal cell models.
Essential Papers
Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions
Rossella Marullo, Erica Werner, Natalya Degtyareva et al. · 2013 · PLoS ONE · 756 citations
Cisplatin is one of the most effective and widely used anticancer agents for the treatment of several types of tumors. The cytotoxic effect of cisplatin is thought to be mediated primarily by the g...
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ganesan Ramesh, William Reeves · 2002 · Journal of Clinical Investigation · 751 citations
The purpose of these studies was to examine the role of cytokines in the pathogenesis of cisplatin nephrotoxicity. Injection of mice with cisplatin (20 mg/kg) led to severe renal failure. The expre...
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Abdullah Özkök, Charles L. Edelstein · 2014 · BioMed Research International · 678 citations
Cisplatin and other platinum derivatives are the most widely used chemotherapeutic agents to treat solid tumors including ovarian, head and neck, and testicular germ cell tumors. A known complicati...
Drug-Induced Oxidative Stress and Toxicity
Damian G. Deavall, Elizabeth A. Martin, Judith Horner et al. · 2012 · Journal of Toxicology · 667 citations
Reactive oxygen species (ROS) are a byproduct of normal metabolism and have roles in cell signaling and homeostasis. Species include oxygen radicals and reactive nonradicals. Mechanisms exist that ...
Cellular Responses to Cisplatin‐Induced DNA Damage
Alakananda Basu, Soumya Krishnamurthy · 2010 · Journal of Nucleic Acids · 551 citations
Cisplatin is one of the most effective anticancer agents widely used in the treatment of solid tumors. It is generally considered as a cytotoxic drug which kills cancer cells by damaging DNA and in...
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity
Vladislav Volarević, Bojana Djokovic, Marina Gazdic et al. · 2019 · Journal of Biomedical Science · 405 citations
Recent Advances in Models, Mechanisms, Biomarkers, and Interventions in Cisplatin-Induced Acute Kidney Injury
Sara J. Holditch, Carolyn Nicole Brown, Andrew M. Lombardi et al. · 2019 · International Journal of Molecular Sciences · 345 citations
Cisplatin is a widely used chemotherapeutic agent used to treat solid tumours, such as ovarian, head and neck, and testicular germ cell. A known complication of cisplatin administration is acute ki...
Reading Guide
Foundational Papers
Start with Marullo et al. (2013, 756 citations) for mitochondrial ROS mechanisms, Ramesh and Reeves (2002, 751 citations) for cytokine roles, and Özkök and Edelstein (2014, 678 citations) for AKI pathophysiology to build core understanding.
Recent Advances
Study Holditch et al. (2019, 345 citations) for biomarkers/interventions, Volarević et al. (2019, 405 citations) for molecular balance, and Fang et al. (2021, 340 citations) for natural product therapies.
Core Methods
Core techniques: ROS/redox assays (Marullo 2013), mitochondrial isolation/apoptosis quantification (dos Santos 2007), mouse AKI models with cytokine blockade (Ramesh 2002), and PGC-1α/mitophagy analysis (Holditch 2019).
How PapersFlow Helps You Research Mitochondrial Dysfunction Cisplatin Nephrotoxicity
Discover & Search
Research Agent uses searchPapers and citationGraph to map 756-citation Marullo et al. (2013) connections, revealing clusters on mitochondrial ROS in cisplatin AKI; exaSearch uncovers hidden mtDNA damage studies, while findSimilarPapers expands from Özkök and Edelstein (2014).
Analyze & Verify
Analysis Agent applies readPaperContent to extract ROS mechanisms from dos Santos et al. (2007), then runPythonAnalysis on mitochondrial bioenergetics data for statistical verification; verifyResponse with CoVe and GRADE grading confirms claims against Ramesh and Reeves (2002) cytokine pathways.
Synthesize & Write
Synthesis Agent detects gaps in mitophagy interventions via contradiction flagging across Holditch et al. (2019) and Volarević et al. (2019); Writing Agent uses latexEditText, latexSyncCitations for 10-paper reviews, latexCompile for figures, and exportMermaid for ETC inhibition diagrams.
Use Cases
"Extract and plot cisplatin mitochondrial ROS data from key papers"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Marullo 2013) → runPythonAnalysis (pandas/matplotlib for ROS vs bioenergetics scatterplot) → researcher gets publication-ready graph with stats.
"Draft LaTeX review on PGC-1α interventions for cisplatin nephrotoxicity"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (10 papers) → latexCompile → researcher gets compiled PDF with synced refs and figures.
"Find GitHub code for mitochondrial fission-fusion models in AKI"
Research Agent → citationGraph (Holditch 2019) → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets validated simulation code for renal mitodynamics.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers → citationGraph on Marullo (2013), generating structured AKI report with GRADE scores. DeepScan's 7-step chain verifies ROS claims from dos Santos (2007) with CoVe checkpoints and Python stats. Theorizer builds hypotheses on mitophagy regulators from Özkök (2014) and Volarević (2019).
Frequently Asked Questions
What defines mitochondrial dysfunction in cisplatin nephrotoxicity?
Cisplatin causes mtDNA damage, ETC inhibition, ROS bursts, and bioenergetic collapse in renal proximal tubules, as shown in Marullo et al. (2013) and dos Santos et al. (2007).
What are key methods studied?
Methods include ROS assays, mitochondrial membrane potential measurement, and PGC-1α/mitophagy modulation; Marullo et al. (2013) used redox status analysis, Özkök and Edelstein (2014) reviewed AKI models.
What are the most cited papers?
Top papers: Marullo et al. (2013, 756 citations) on mitochondrial ROS; Ramesh and Reeves (2002, 751 citations) on TNF-α; Özkök and Edelstein (2014, 678 citations) on AKI pathophysiology.
What open problems exist?
Challenges include selective renoprotection without tumor resistance (Volarević et al., 2019), mitophagy biomarkers (Holditch et al., 2019), and in vivo ETC repair validation.
Research Chemotherapy-induced organ toxicity mitigation with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mitochondrial Dysfunction Cisplatin Nephrotoxicity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers